Incivek™ (telaprevir) and Hepatitis C
What is Incivek™ (telaprevir)?
UPDATE: As of August 2014 Vertex announced it will discontinue selling Incivek.
On May 23, 2011, the U.S. Food and Drug Administration approved the prescription medication Incivek™ (telaprevir) for use in combination with peginterferon alfa and ribavirin to treat chronic Hepatitis C genotype 1 infection in adult patients who have not been treated before or who have failed previous treatment. The active ingredient in this 375 mg tablet is telaprevir.
Incivek™ is a Hepatitis C virus (HCV) NS3/4A protease inhibitor which works by binding to the virus and preventing it from multiplying. It is to be used in combination with peginterferon and ribavirin. It is not to be used alone.
Last Updated: July 2014
Vertex Pharmaceuticals "Highlights of Prescribing Information - Incivek™" http://pi.vrtx.com/files/uspi_telaprevir.pdf. Retrieved May 23, 2011.
Vertex Pharmaceuticals "Medication Guide - Incivek™" http://pi.vrtx.com/files/usmedguide_telaprevir.pdf. Retrieved May 23, 2011.
Vertex Pharmaceuticals "For Patients - Helping People Get Incivek™ (telaprevir) tablets" http://www.vrtx.com/patients.html. Retrieved May 23, 2011.
- What is Incivek™ (telaprevir)?
- What is the dosage for Incivek™ (telaprevir)?
- Does the dosage and administration of Incivek™ (telaprevir) differ for various people?
- When is Incivek™ contraindicated?
- What types of adverse reactions were reported when taking Incivek™?
- Are there any other warnings one should know regarding Incivek™ combination therapy?
- At what point would one know the Incivek™ combination therapy is not working?
- Can those co-infected with HIV and Hepatitis C begin Incivek™ combination therapy?
- When can I get a prescription for Incivek™ (telaprevir)?
- How can I get assistance paying for Incivek™ (telaprevir)? Is Incivek™ covered by insurance?